AsCNP/JSNP/JSCNP 2019

Session information

[CNP] Symposium

CNP » [CNP] Symposium

[CNP_S2] Symposium2
Aims and scope for schizophrenia pharmacotherapy guidelines revised edition

Fri. Oct 11, 2019 8:40 AM - 10:20 AM Room 3 (413+414)

オーガナイザー:古郡 規雄(獨協医科大学精神神経医学講座)、座長:中込 和幸(国立精神・神経医療研究センター)、染矢 俊幸(新潟大学大学院医歯学総合研究科精神医学分野)

精神科薬物療法については、臨床家ごとのばらつきが大きく、よりよい医療を普及させることが必要とされている。抗精神病薬の単剤治療を行うことが海外の各種ガイドラインで推奨されているが、本邦では諸外国と比較して突出して抗精神病薬の多剤投与が多く薬剤数が多い。抗精神病薬の多剤併用率が65%程度であり、抗パーキンソン薬、抗不安薬/睡眠薬、気分安定薬の併用率もそれぞれが30-80%と高い。そして、2014年には、向精神薬の多剤処方に対する診療報酬の減額がなされた。本邦においては、統合失調症の薬物治療ガイドラインが2015年9月に日本神経精神薬理学会より発表された。このガイドラインは、精神科分野においては本邦初のMinds法を用いたエビデンスに基づいたもので、現在CNPとNPが合同で統合失調症薬物治療ガイドライン改訂版が作成されている。本シンポジウムでは各パートの進捗状況を報告する予定である。

8:56 AM - 9:08 AM

Hiroyoshi TAKEUCHI1, Tetsufumi KANAZAWA2, Koki ITO3, Kazuto OYA4 (1. Department of Neuropsychiatry, Keio University School of Medicine, 2. Department of Neuropsychiatry, Osaka Medical College, 3. Department of Psychiatry, Hokkaido University School of Medicine, 4. Department of Psychiatry, Fujita Health University School of Medicine)

9:08 AM - 9:20 AM

Aran TAJIKA1, Seiichiro TARUTANI2, Hikaru HORI 3, Yuki MATSUDA4, Atsunobu MURATA5, Taishiro KISHIMOTO6 (1. Department of Psychiatry, Kyoto University Hospital, 2. Shin-Abuyama Hospital, Osaka Institute of Clinical Psychiatry, 3. Department of Psychiatry, School of Medicine, University of Occupational and Environemental Health, 4. Department of Psychiatry Jikei University School of Medicine, 5. Kyowa Hospital Pharmacy, 6. Department of Neuropsychiatry, Keio University School of Medicine)

9:20 AM - 9:32 AM

Yoshiteru TAKEKITA1, Shunichiro IKEDA1, Shusuke NUMATA2, Enami SAWAYAMA3, Hiroshi KIMURA4, 5, Ikuo NOMURA6, 7, Taro SUWA8 (1. Department of Neuropsychiatry, Kansai Medical University, 2. Department of Psychiatry,Graduate School of Biomedical Science, Tokushima University, 3. Department of Psychiatry, Kitasato University School of Medicine, 4. Department of psychiatry, Gakuji-Kai Kimura Hospital, 5. Department of psychiatry, Graduate School of Medicine, Chiba University, 6. Department of Psychiatry, Fujita Health University School of Medicine, 7. Department of Psychiatry, Moriyama Integrated Mental Care Hospital, 8. Department of Psychiatry, Graduate School of Medicine, Kyoto University )

9:44 AM - 9:56 AM

Takashi TSUBOI1, Masakazu HATANO2, Tsutomu NAGAI3, Tsuyoshi SASAKI4, Haruhiko ODA5, Satoru ESUMI6, Hiroki YAMADA7, Hiroshi KADOTANI8, Yasuhiko HASHIMOTO9, Tetsu TOMITA10 (1. Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan, 2. Department of Clinical Pharmacy, Fujita Health University School of Medicine, Aichi, Japan, 3. Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan, 4. Department of Child Psychiatry, Chiba-University Hospital, Chiba, Japan, 5. Hyogo Mental Health Center, Hyogo, Japan, 6. Department of Pharmacy, Okayama University Hospital, Okayama, Japan, 7. Department of Psychiatry, School of Medicine, Showa University, Tokyo, Japan, 8. Department of Sleep and Behavioral Sciences, Shiga University of Medical Science, Shiga, Japan, 9. Factly of clinical pharmacy, KobeGakuin university, Hyogo, Japan, 10. Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Aomori, Japan)

10:08 AM - 10:20 AM

Omi WATANABE1, Kiyotaka NEMOTO2, Takaaki YASUDA3, Saya KIKUCHI4, Masanobu ITO5, Toshihito SUZUKI6 (1. Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, 2. Department of Psychiatry, Faculty of Medicine, University of Tsukuba, 3. Department of Psychiatry, Saitama Medical Center, Saitama Medical University, 4. Department of Psychiatry, Tohoku University Hospital, 5. Department of Psychiatry, Juntendo University Faculty of Medicine, 6. Department of Psychiatry, Juntendo Koshigaya Hospital, Juntendo University School of Medicine)